1. Home
  2. UNB vs ADCT Comparison

UNB vs ADCT Comparison

Compare UNB & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Union Bankshares Inc.

UNB

Union Bankshares Inc.

HOLD

Current Price

$23.78

Market Cap

121.6M

Sector

Finance

ML Signal

HOLD

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

HOLD

Current Price

$1.36

Market Cap

136.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UNB
ADCT
Founded
1891
2011
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
121.6M
136.1M
IPO Year
1999
2019

Fundamental Metrics

Financial Performance
Metric
UNB
ADCT
Price
$23.78
$1.36
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$7.75
AVG Volume (30 Days)
4.6K
1.7M
Earning Date
04-15-2026
05-04-2026
Dividend Yield
5.76%
N/A
EPS Growth
25.52
30.86
EPS
1.25
N/A
Revenue
N/A
$81,357,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$66.49
P/E Ratio
$19.17
N/A
Revenue Growth
N/A
14.85
52 Week Low
$20.65
$0.78
52 Week High
$26.54
$4.98

Technical Indicators

Market Signals
Indicator
UNB
ADCT
Relative Strength Index (RSI) 50.72 61.38
Support Level $23.58 $1.03
Resistance Level $24.49 $1.45
Average True Range (ATR) 0.32 0.08
MACD 0.01 0.04
Stochastic Oscillator 46.87 83.37

Price Performance

Historical Comparison
UNB
ADCT

About UNB Union Bankshares Inc.

Union Bankshares Inc operates as a community bank in the financial services industry. It offers retail and commercial banking services to its customers through its branches, ATMs, telebanking, and internet banking systems. The Company has one definable business segment, Union Bank, which provides full retail, commercial, municipal banking, and wealth management and trust services throughout its 18 branch banking locations, three loan centers, and several ATMs covering northern Vermont and northern New Hampshire. In addition, it also offers fiduciary and asset management services through its Asset Management Group.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: